Tag: CD20xCD3 T-cell engager

Home / CD20xCD3 T-cell engager

Categories

The FDA has granted expedited approval to epcoritamab-bysp for the treatment of R/R follicular lymphoma

June 2024: The Food and Drug Administration has given accelerated approval to epcoritamab-bysp (Epkinly, Genmab US, Inc.), a bispecific CD20-directed CD3 T-cell engager, for adult patients with recurr...
cd20xcd3-t-cell-engager

Scan the code